Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Atara Biotherapeutics, Inc.

< Previous 1 2 3 4 Next >
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Announces $36 Million Registered Direct Offering
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Announces 1-for-25 Reverse Stock Split
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.